💊 Obesity Watch: AI, GLP-1 Rivals, and $Billion Pharma Moves
In this week’s Obesity Updates, we spotlight game-changing innovations, global partnerships, and next-gen therapies making headlines in metabolic health.
Key updates include:
🚀 Biophytis kicks off a Phase 2 trial for BIO101 to preserve muscle during GLP-1 therapy
💊 Syntis Bio’s SYNT-101 mimics gastric bypass—without surgery
🇨🇳 Hengrui’s injectable therapy gets NMPA approval in China
🤖 Northstrive & Yuva team up on AI-powered obesity drugs
💥 Roche and Zealand strike a $5.3B deal to challenge GLP-1 leaders
🧬 Dong-A ST’s microneedle patch shows greater than 60 percent bioavailability
🇧🇷 Novo invests $1.1B in Brazil to expand global supply of Wegovy and Ozempic
🧪 Xenical sees renewed demand as obesity rates climb
🌐 Novo Nordisk partners with Tencent to tackle obesity digitally in China
📱 MyMedipro launches a digital obesity platform in Japan powered by gamification
From injectable breakthroughs and oral alternatives to digital health innovations, this episode dives into the evolving landscape of obesity management and metabolic care.
📢 Stay Ahead in Obesity Research!
✅ Like, share, and subscribe for weekly updates on Obesity
#ObesityCare #BiotechNews #GLP1 #DigitalHealth #MetabolicHealth #PharmaInnovation #WeightLossResearch #LucidQuest #ObesityDrugDevelopment #HealthcareConsulting #Microneedles #AmylinAnalog #NovoNordisk #Biophytis #Roche #Zealand #Zealand #SyntisBio #ObesityTreatment #ClinicalTrials #MedicalBreakthroughs